Company Overview: Profound Medical Corp. (TSX: PRN) is a commercial-stage medical technology company focused on developing innovative interventional MRI (iMRI) solutions. Its flagship product, TULSA-PRO®, is an MRI-guided, incision-free prostate tissue ablation system that enables precise and personalized treatment of prostate diseases while minimizing damage to surrounding healthy tissues. The company serves businesses with integrated communication and collaboration solutions. This Report covers Price Action, Technical Indicators Analysis along with the Stop Loss Levels, Target Prices, and Recommendation on this one stock.

Canada Market Round-Up

The S&P/TSX Composite Index ended the week ended October 9, 2026, on a positive note, advancing 0.46% to close at 35,664.62, although the pace of its recent gains has moderated. From a technical perspective, the outlook remains cautiously bullish, as the index continues to hold above its horizontal trendline support and 21-day Simple Moving Average (SMA), indicating underlying strength and continued buying interest on market dips. The daily 14-period Relative Strength Index (RSI) stands at 49.96, reflecting positive momentum while leaving room for potential consolidation or short-term profit-taking. Looking ahead, immediate resistance is positioned near 36,377.91. A decisive breakout above this level could reinforce bullish sentiment and support further upside. On the downside, immediate support lies near 34,951.33, where renewed buying interest could help sustain the prevailing uptrend. However, a sustained break below this support level could weaken the technical outlook and increase the risk of a deeper corrective decline.

On the macro front, the upcoming major economic events that may impact the Canadian market sentiment include CA CPI m/m, US Retail Sales m/m and US Unemployment Claims.

Past performance is not a reliable indicator of future performance.